electroCore, Inc.
NASDAQ:ECOR
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
electroCore, Inc.
Accounts Receivables
electroCore, Inc.
Accounts Receivables Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Accounts Receivables | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
electroCore, Inc.
NASDAQ:ECOR
|
Accounts Receivables
$1m
|
CAGR 3-Years
37%
|
CAGR 5-Years
28%
|
CAGR 10-Years
N/A
|
|
|
Boston Scientific Corp
NYSE:BSX
|
Accounts Receivables
$2.9B
|
CAGR 3-Years
14%
|
CAGR 5-Years
14%
|
CAGR 10-Years
9%
|
|
|
Edwards Lifesciences Corp
NYSE:EW
|
Accounts Receivables
$659.6m
|
CAGR 3-Years
1%
|
CAGR 5-Years
5%
|
CAGR 10-Years
8%
|
|
|
Stryker Corp
NYSE:SYK
|
Accounts Receivables
$4B
|
CAGR 3-Years
4%
|
CAGR 5-Years
8%
|
CAGR 10-Years
9%
|
|
|
Abbott Laboratories
NYSE:ABT
|
Accounts Receivables
$7.9B
|
CAGR 3-Years
10%
|
CAGR 5-Years
5%
|
CAGR 10-Years
9%
|
|
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
Accounts Receivables
$1.5B
|
CAGR 3-Years
17%
|
CAGR 5-Years
19%
|
CAGR 10-Years
15%
|
|
electroCore, Inc.
Glance View
electroCore, Inc. engages in the provision of non-invasive vagus nerve stimulation (nVNS) therapy. The company is headquartered in Rockaway, New Jersey and currently employs 52 full-time employees. The company went IPO on 2018-06-22. nVNS is a platform for bioelectronic medical therapy that modulates neurotransmitters and immune function through its effects on both the peripheral and central nervous systems. The firm is providing gammaCore device for the treatment of cluster headache and migraine, the acute treatment of migraine and episodic cluster headache, the acute and preventive treatment of migraines in adolescents, and paroxysmal hemicrania and hemicrania continua in adults. gammaCore permits patients to self-administer doses of nVNS on an as-needed basis for treatment of prevent multiple types of headache pain via the vagus nerve. The gammaCore therapy is also used to treat primary headache, including migraine, cluster headache (CH), hemicrania continua and paroxysmal hemicrania (PH) and coronavirus (COVID-19).
See Also
What is electroCore, Inc.'s Accounts Receivables?
Accounts Receivables
1m
USD
Based on the financial report for Dec 31, 2025, electroCore, Inc.'s Accounts Receivables amounts to 1m USD.
What is electroCore, Inc.'s Accounts Receivables growth rate?
Accounts Receivables CAGR 5Y
28%
Over the last year, the Accounts Receivables growth was -25%. The average annual Accounts Receivables growth rates for electroCore, Inc. have been 37% over the past three years , 28% over the past five years .
